"Heavy first" super antibiotics, phosphatamine approved in our country!
-
Last Update: 2019-03-12
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
original title: "Heavy first" super antibiotics, phosphatamine approved in our country!On March 4, 2019, Bayer Pharmaceuticals' Tedizolidphosphate tablets and injections were approved for the market by the China Drug Administration (NMPA)Approved indications may be adult acute skin and tissue infections (ABSSSI) caused by Gram-positive bacteriaProduct specifications: tablets/200mg;Note: Pharmaceutical Melt Data, Pharnex Datamonitor; NMPAIt takes about 21 months from listing to approvalphosphate pyridine was first developed by Dong-A Pharmaceuticals of Korea, a second-generation antibiotic, which was licensed for commercial development by Trius Therapeutics, Cubist (Merck and Co) and Bayer, and was approved by the U.SFDA on June 20, 2014 and listed in the European Union in June 20, 2015In China compound patent ZL200480037612.2, the protection period to 2024.12.17currently receiving pneumonia in the hospital of Tedizolidphosphate (code: TR-701) was completed in Phase III clinical studies in 2018the main purpose of this clinical study is to determine the non-disadvantage (NI) of total cause mortality (NI) on 28 days compared to linamolamine therapyThe international multi-center trial totaled 726 people, with 18 in Chinareference:NMPA/CDE;, Pharnex Datamonitor; Pharmaceutical syntheFDA/EMA; public disclosure byrelated companies; , etc
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
